You are here

A non-myeloablative conditioning regimen for hematopoietic stem cell transplantat

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL117576-01A1
Agency Tracking Number: R43HL117576
Amount: $366,718.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
10101 Alliance Rd
CINCINNATI, OH 45242-4739
United States
DUNS: 182472162
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HARTMUT GEIGER
 (513) 636-1338
 hartmut.geiger@cchmc.org
Business Contact
 RENEE O'CONNOR
Phone: (513) 476-6618
Email: rmoconnor@p2dinc.com
Research Institution
 Stub
Abstract

Abstract Hematopoietic stem cell transplantation (HSCT) has become a standard care for the treatment of many hematologic malignancies and non-malignant diseases such as bone marrow failure and immunodeficiency syndromes. Currently, myeloablative or irradiative conditioning regimens are used for enhancing HSC engraftment in transplantation, but they are often associated with significant morbidity and mortality, particularly in patients under severe clinical or pathological stress. In addition, in many clinical cases only limited numbers of HSCs are available for transplant. Improving efficiency of BM niche access will improve HSCT outcomes by increasing donor chimerism in clinical settings where stem cell numbers are limiting and recipients are fragile, e.g.in cord blood or gene therapy transplants. As an important intracellular signal transducer of multiple cell stimuli required for HSC maintenance, including signaling from receptor tyrosine kinase c-Kit, chemokine receptor CXCR4 and adhesion receptor integ

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government